Pharmaceutical

Syngenta collaborates with Ginkgo Bioworks to enable faster launch of innovative biologicals

Syngenta will leverage Ginkgo's Ag Biologicals capabilities to optimize secondary metabolite production for a pioneering biological solution BASEL, Switzerland and…

6 months ago

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

Live video webcast with Chief Executive Officer, John Climaco, on Wednesday, June 17th at 4:00 PM ET HOUSTON, TX /…

6 months ago

Trethera Receives $2M NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis

LOS ANGELES, July 16, 2024 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs…

6 months ago

Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada

July 16, 2024 Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada Biodexa Pharmaceuticals…

6 months ago

Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Complete enrollment achieved nearly six months ahead of plan Top-line data now anticipated mid-2025 Addition of second-line cholangiocarcinoma arm to…

6 months ago

Recce Pharmaceuticals Receives $2 Million Grant from U.S. Department of Defense for RECCE® 327 Gel

Funding to accelerate development of RECCE® 327 Gel (R327G) for acute treatment of burn wound infections and downstream bacterial complications…

6 months ago

Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission

Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin…

6 months ago

Algernon Pharmaceuticals Reports Results of Study Showing 93% Cough Suppression with Ifenprodil

VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or…

6 months ago

VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor

BRIDGEWATER, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical…

6 months ago

Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones

DURHAM, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable,…

6 months ago